Priveterra Acquisition Corp. II: Nasdaq/NYSE listing notice — Priveterra Acquisition Corp. II receives additional Nasdaq delinquency notice; exception extended to July 8, 2024

Priveterra Acquisition Corp. II

Received additional Nasdaq notice on April 29, 2024 for failure to file Annual Report on Form 10-K for year ended Dec 31, 2023.
Prior delisting exception granted by Nasdaq Hearings Panel extended to July 8, 2024, subject to filing S-4 by April 30, 2024.
Company must demonstrate compliance with all initial listing standards by July 8, 2024.
The new delinquency may serve as separate basis for delisting; Panel will consider it.
Company must present views on additional deficiency to Panel in writing by May 6, 2024.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Priveterra Acquisition Corp. II received a nasdaq deficiency notice notice regarding other (rules 5250(c)(1)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5250(c)(1)

Exact text from the filing

April 29, 2024, the Company received an additional notice (the “Additional Notice”) from the staff of the Listing Qualifications Department of Nasdaq indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) since it has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023. The Additional Notice indicates that such additional delinquency may serve as a separate basis for the delisting of the Company’s securities from Nasdaq, that the Panel will consider this matter in their decision regarding the Company’s continued listing on The N

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-056959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.